Compare Freeport-McMoRan Inc (FCX) vs Summit Therapeutics Inc (SMMT) Price & Performance

FCX trades at $73.29, up 1.98% on the day, with a bearish technical signal but strong fundamental support. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue is stable at $25.9B (2025), and net income margin improved to 11.38%. Analyst consensus is a Buy (60.97%), with a price target of $73.27. Recent news highlights copper demand growth driven by AI and data centers, positioning FCX to benefit.

FCX offers exposure to rising copper demand, supported by operational efficiency and expansion projects. Risks include cost pressures and regulatory scrutiny. The stock's valuation metrics (P/E 34.87, P/S 3.97) suggest premium pricing, requiring sustained earnings growth to justify upside. Institutional sentiment remains positive, but investors should monitor Q3 earnings and copper price trends.

Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.

The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.